{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:40:27Z","timestamp":1772120427266,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.lungcan.2012.05.108","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T19:21:04Z","timestamp":1340220064000},"page":"515-521","source":"Crossref","is-referenced-by-count":28,"title":["HER family receptor and ligand status in thymic carcinoma"],"prefix":"10.1016","volume":"77","author":[{"given":"Annikka","family":"Weissferdt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Woods","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2012.05.108_bib0005","series-title":"Tumours of the lung, pleura, thymus and heart","first-page":"148","year":"2004"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/erc.0.0100001","article-title":"Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment","volume":"10","author":"Normanno","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ctrv.2010.07.004","article-title":"Use of molecular markers for predicting therapy response in cancer patients","volume":"37","author":"Duffy","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.lungcan.2012.05.108_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1746-1596-1-19","article-title":"Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay","volume":"15","author":"Varella-Garcia","year":"2006","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0035","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","article-title":"KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"13","author":"Massarelli","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"Suppl. 4","key":"10.1016\/j.lungcan.2012.05.108_bib0040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities","volume":"37","author":"Yarden","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1389450053765879","article-title":"The ErbB receptors and their ligands in cancer: an overview","volume":"6","author":"Normanno","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0050","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0060","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-4827(02)00099-X","article-title":"The ErbB receptors and their role in cancer progression","volume":"284","author":"Holbro","year":"2003","journal-title":"Exp Cell Res"},{"issue":"Suppl. 1","key":"10.1016\/j.lungcan.2012.05.108_bib0070","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0169-5002(03)00137-5","article-title":"Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies","volume":"41","author":"Hirsch","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0075","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/cncr.20811","article-title":"Protein expression and gene amplification of epidermal growth factor receptor in thymomas","volume":"103","author":"Ionescu","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0080","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/jjco\/hyl028","article-title":"Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors","volume":"36","author":"Suzuki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2559.2003.01663.x","article-title":"Expression of apoptosis-related markers and HER-2\/neu in thymic epithelial tumours","volume":"43","author":"Pan","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2006.07.003","article-title":"Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas","volume":"248","author":"Meister","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0100","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","article-title":"Epidermal growth factor receptor, C-kit, and Her2\/neu immunostaining in advanced or recurrent TENs staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study","volume":"5","author":"Aisner","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00194697","article-title":"Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21","volume":"426","author":"Hayashi","year":"1995","journal-title":"Virchows Arch"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2006.01.009","article-title":"Thymic carcinoma with epidermal growth factor receptor gene mutations","volume":"52","author":"Yamaguchi","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0120","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1183\/09031936.02.00296502","article-title":"The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis","volume":"20","author":"Meert","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0125","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/sj.bjc.6600286","article-title":"Evaluation of HER-2\/neu gene amplification and protein expression in non-small cell lung carcinomas","volume":"86","author":"Hirsch","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0130","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/JTO.0b013e3181f26266","article-title":"The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data","volume":"5","author":"Liu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1479-5876-9-126","article-title":"Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma","volume":"9","author":"Takikita","year":"2011","journal-title":"J Transl Med"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0140","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1200\/JCO.2010.33.6313","article-title":"Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome","volume":"29","author":"Begnami","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0145","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12032-009-9178-z","article-title":"Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer","volume":"27","author":"Kim","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0150","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/j.1349-7006.2011.01999.x","article-title":"Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities","volume":"102","author":"Kondo","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0155","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1126\/science.2422759","article-title":"Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor","volume":"232","author":"Schreiber","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0160","first-page":"119","article-title":"The multiple roles of amphiregulin in human cancer","volume":"1816","author":"Busser","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0165","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1158\/0008-5472.226.65.1","article-title":"Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer","volume":"65","author":"Amann","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0170","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1158\/0008-5472.CAN-05-1556","article-title":"Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers","volume":"65","author":"Ishikawa","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0175","first-page":"241","article-title":"Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I\u2013IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival","volume":"4","author":"Fontanini","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0180","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1200\/JCO.2010.31.0805","article-title":"Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21","volume":"28","author":"Addison","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/1940-6207.CAPR-08-0014","article-title":"Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells","volume":"1","author":"Zhang","year":"2008","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0190","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1158\/0008-5472.CAN-06-0404","article-title":"Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells","volume":"66","author":"Castillo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0195","doi-asserted-by":"crossref","first-page":"49127","DOI":"10.1074\/jbc.M207584200","article-title":"Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines","volume":"277","author":"Hurbin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI29518","article-title":"Targeting TACE-dependent EGFR ligand shedding in breast cancer","volume":"117","author":"Kenny","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0205","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ijc.2910620619","article-title":"Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line","volume":"62","author":"Normanno","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Str\u00f6bel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2012.05.108_bib0215","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212003777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212003777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T20:25:33Z","timestamp":1687551933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500212003777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0169500212003777"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2012.05.108","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}